Skip to main content

Table 4 Association of IL2RA mRNA expression with prognosis relevant variables in CBF, intermediate-risk and poor-risk AML

From: High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia

  CBF AML Intermediate-risk AML Poor-risk AML
High IL2RA mRNA Low IL2RA mRNA p-value High IL2RA mRNA Low IL2RA mRNA p-value High IL2RA mRNA Low IL2RA mRNA p-value
Age group 0.026   0.813   0.348
 15–29 5 (9) 16 (45)   8 (30) 26 (118)   1 (9) 9 (28)  
 30–49 1 (9) 25 (45)   15 (30) 59 (118)   3 (9) 10 (28)  
 50–65 3 (9) 4 (45)   7 (30) 33 (118)   5 (9) 9 (28)  
High WBC counts 2 (8) 12 (30) 0.686 9 (18) 29 (78) 0.423 1 (9) 5 (23) 0.648
High blast percentage 5 (9) 32 (45) 0.439 18 (30) 72 (118) 1.000 3 (9) 19 (28) 0.118
Secondary AML 0 (9) 0 (45) NA 1/30 2/118 0.496 2/9 3 (28) 0.577
FLT3-ITD+ 2 (7) 0 (36) 0.023 17 (27) 14 (90) < 0.001 2 (7) 3 (25) 0.296
NPM1+ 0 (7) 0 (36) NA 8 (27) 28 (90) 1.000 0 (7) 0 (25) NA
NPM1+FLT3-ITD 0 (7) 0 (36) NA 0 (27) 22 (90) 0.002 0 (7) 0 (25) NA
CEBPADM+ 0 (7) 0 (36) NA 1 (27) 18 (90) 0.070 0 (7) 0 (25) NA
c-Kit D816V+ 1 (7) 4 (36) 1.000 0 (27) 1 (90) 1.000 0 (7) 1 (25) 1.000
  1. The number in the parentheses is the number of patients that are of high or low IL2RA expression tested in that particular parameter
  2. NA not applicable
  3. *The p value for RFS and OS is calculated by Kaplan–Meier log-rank test. The p value for the other parameters are calculated by Fisher’s exact test or Chi-Square test